Anele Uzoma A, Le Brian V, Resar Linda M S, Burnett Arthur L
The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD;
Division of Hematology, Department of Medicine, Department of Oncology, and Institute for Cellular Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD.
Blood. 2015 Jun 4;125(23):3551-8. doi: 10.1182/blood-2014-09-551887. Epub 2015 Mar 25.
Priapism is a disorder of persistent penile erection unrelated to sexual interest or desire. This pathologic condition, specifically the ischemic variant, is often associated with devastating complications, notably erectile dysfunction. Because priapism demonstrates high prevalence in patients with hematologic disorders, most commonly sickle cell disease (SCD), there is significant concern for its sequelae in this affected population. Thus, timely diagnosis and management are critical for the prevention or at least reduction of cavernosal tissue ischemia and potential damage consequent to each episode. Current guidelines and management strategies focus primarily on reactive treatments. However, an increasing understanding of the molecular pathophysiology of SCD-associated priapism has led to the identification of new potential therapeutic targets. Future agents are being developed and explored for use in the prevention of priapism.
阴茎异常勃起是一种与性兴趣或欲望无关的持续性阴茎勃起障碍。这种病理状况,特别是缺血性变体,通常与严重并发症相关,尤其是勃起功能障碍。由于阴茎异常勃起在血液系统疾病患者中具有较高的患病率,最常见的是镰状细胞病(SCD),因此人们对该受影响人群中的后遗症深感担忧。因此,及时诊断和管理对于预防或至少减少每次发作导致的海绵体组织缺血和潜在损伤至关重要。当前的指南和管理策略主要侧重于反应性治疗。然而,对SCD相关性阴茎异常勃起分子病理生理学的日益了解已导致识别出新的潜在治疗靶点。正在开发和探索未来用于预防阴茎异常勃起的药物。